AXL and neoplasm: Targeting Axl in animal tumor models with small molecule tyrosine kinase inhibitors (TKIs), monoclonal antibodies (mAb) or decoy fusion protein have been demonstrated to be able to inactivate Axl-mediated signaling pathways leading to metastasis inhibition, recovered drug sensitivity and improved therapeutic efficacy, defining Axl as a promising novel target for cancer therapeutics [9, 15, 16].